Obstetrics and Gynecology Group Practice in Medicum Facharztzentrum and St, Josefs Hospital Wiesbaden, Langenbeckplatz 2, 65189, Wiesbaden, Germany.
Obstetrics and Gynecology, Division of Clinical Genetics, Feinberg School of Medicine of Northwestern University, Chicago, USA.
Adv Ther. 2022 Jun;39(6):2438-2451. doi: 10.1007/s12325-022-02157-7. Epub 2022 Apr 30.
Iron deficiency (ID), with or without anemia, is commonly found worldwide and affects the health and wellbeing of pregnant and nonpregnant women. Symptoms of ID- which include fatigue, pica (ice craving), restless legs syndrome, poor concentration and work function, increased susceptibility to infection, and cardiovascular stress- can cause significant morbidity and reduced quality of life. The etiologies of iron deficiency in women are usually specific to each community. In the developing world, iron deficiency is usually associated with poor iron intake and parasitic infections, whereas in higher income regions, iron deficiency is typically the result of heavy, abnormal uterine bleeding, and pregnancy. Iron-poor diets and poor iron absorption resulting from gut disorders can also play a role. Diagnosis of iron deficiency is usually straightforward and characterized by a low ferritin level; however, the diagnosis can be challenging in women with concomitant inflammatory disorders, in which case a low percent transferrin saturation, performed after an overnight fast, can inform on the need for iron. Therapy is frequently initiated with oral iron salts; however, use of these oral regimens is commonly associated with adverse events, mostly gastrointestinal in nature, that have been shown to adversely impact compliance, continuation, and the achievement of therapeutic goals. A further impediment to the effectiveness of oral iron is its poor absorption because of comorbidity (i.e., celiac disease, gastritis, etc.), surgery (bariatric), or physiologic inhibitory mechanisms. As such, intravenous (IV) iron regimens are increasingly being used to treat ID, as such regimens have been shown to avoid the gastrointestinal adverse events commonly associated with oral regimens. Indeed, IV iron has been shown to provide adequate iron replacement in women with functional iron deficiencies as well as those with ID resulting from inflammatory disorders- patients often resistant to oral iron therapy. More recent IV iron regimens have been shown to provide iron replacement in a safe and effective manner, being associated with more salutary adverse event profiles than earlier IV iron regimens. In fact, these iron regimens can provide a complete replacement dose in a single 15-60-min visit.
缺铁(ID),无论是否伴有贫血,在全球范围内都很常见,影响着孕妇和非孕妇的健康和幸福。缺铁的症状包括疲劳、异食癖(渴望吃冰)、不安腿综合征、注意力不集中和工作能力下降、易感染以及心血管压力等,会导致严重的发病率和生活质量下降。女性缺铁的病因通常与每个社区的具体情况有关。在发展中国家,缺铁通常与铁摄入不足和寄生虫感染有关,而在高收入地区,缺铁通常是由于大量、异常的子宫出血和怀孕引起的。缺铁饮食和肠道疾病导致的铁吸收不良也可能起作用。缺铁的诊断通常很简单,其特征是铁蛋白水平低;然而,对于同时患有炎症性疾病的女性,诊断可能具有挑战性,在这种情况下,进行隔夜禁食后的低转铁蛋白饱和度百分比测定,可以提示是否需要补铁。治疗通常采用口服铁盐开始;然而,这些口服方案的使用常与不良事件相关,主要是胃肠道性质的,这已被证明会对依从性、持续治疗和治疗目标的实现产生不利影响。口服铁的吸收不良也进一步阻碍了其疗效,原因是合并症(例如乳糜泻、胃炎等)、手术(减肥手术)或生理抑制机制。因此,越来越多地使用静脉(IV)铁剂来治疗 ID,因为这些方案已被证明可以避免与口服方案相关的胃肠道不良事件。事实上,IV 铁已被证明可以为功能缺铁和由炎症性疾病引起的缺铁的女性提供足够的铁替代治疗,这些女性往往对口服铁治疗有耐药性。最近的 IV 铁剂方案已被证明以安全有效的方式提供铁替代治疗,与早期 IV 铁剂方案相比,其不良反应谱更有益。事实上,这些铁剂方案可以在一次 15-60 分钟的就诊中提供完整的替代剂量。